New Data on Trastuzumab Deruxtecan Shows Promising Outcomes in HER2-Positive Metastatic Breast Cancer with Brain Metastases: Results from DESTINY-Breast12

Nancy U. Lin, MD from Dana-Farber Cancer Institute, Boston, Massachusetts, USA, presented late-breaking results from the phase IIIb/IV DESTINY-Breast12 trial at the 2024 ESMO Congress. The open-label trial evaluated Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (mBC), including those with brain metastases.